Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02252 MEDBOT-B
RT Nominal down9.990 -0.450 (-4.310%)

09/07/2024 13:03

{Block Trade}MEDBOT-B (02252): 1.88m shares, or HK$15.44m

[ET Net News Agency, 9 July 2024] A direct manual trade of 1.88 million shares of
MEDBOT-B (02252) was registered at 1:02p.m.
The deal amounted to HK$15.44m, or at HK$8.23 per share, 4% lower than previous close.
MEDBOT-B is now trading down 3.97% to HK$8.23, with 2.23 million shares of HK$18.46m
changing hands. (rw)

Back to Block Trade News

Previous︰11/12/2024 15:46  {Block Trade}MEDBOT-B (02252): 4.27m shares, or HK$50.66m

Remark: Real time quote last updated: 30/12/2024 17:15
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.